Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Flying High With Record-Breaking First Novel Launch Tally in 2021

New Active Substance Launches Nearing Triple Figures

Executive Summary

2021 was another record-breaking year for novel product launches as COVID-19 continued to make an impact, but the industry’s response to the pandemic did not fully account for the acceleration seen in this strict measure of R&D productivity.

You may also be interested in...



What’s Next At Dr Reddy’s: Biologics CDMO, Cell And Gene Therapy Push

Indian firms are getting their act together in areas like cell and gene therapy, with Dr Reddy’s aiming big and readying a facility alongside an alliance with a Chinese firm for a CAR-T therapy. The company is also doubling down in contract development and manufacturing, with an eye on opportunities in biologics.

Juicy Apples Come From Healthy Trees: Advice For Platform Developers

Speaking at BIO-Europe Spring, three leaders of platform life sciences companies offer advice on their scalable and lower risk business models that support innovation within partner biopharma companies.

Pfizer And Shionogi Form Vanguard In New Subscription Assault On Antibiotic Resistance

Two antibiotics from Pfizer and Shionogi are to be rolled out by the UK’s NHS in a pioneering subscription deal that hopes to encourage antibiotic R&D by delinking payment from volume of use.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC146186

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel